NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

Inquirig,

Too funny as these comments refuse to take into account that SOC crossover led to being on an active comparator. This was good for the patients, right from the regulator point of view to do what is best for the patients but made distinguishing benefit from early treatment vs later treatment impossible to compare within the original trial parameters insisted upon by regulators. This and the regulators forcing SOC/placebo to be under enrolled was an interference that they could be held accountable for if a pathway to approval was not created.
Besides this, the exceptions to adequate and well controlled studies allows for changes in methods used to determine true treatment effect when existing ones turn out to be inadequate to measure it. Hence the SAP was put in place before unblinding and comparators created by an independent group of researchers to greatly reduce the chance for unwanted bias. It is their reputations that are on the line for creating and using the data they did for the ECA comparators.
Trying to link NWBO to these comparators is a deliberate lie perpetrated by those whose “opinions” include pointing to NWBO being responsible for their composition which is blatant lie that you said if anyone could point out that you would admit to. Shall I go on?; ). Best wishes .